Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

13.8%

4 terminated out of 29 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed with results

Key Signals

6 with results60% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (9)
Early P 1 (1)
P 1 (6)
P 2 (8)
P 3 (1)

Trial Status

Active Not Recruiting10
Completed6
Recruiting6
Terminated4
Withdrawn3

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT04789681Phase 2Recruiting

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

NCT04751747Not ApplicableActive Not Recruiting

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT02194738Not ApplicableActive Not Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT04183218Completed

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

NCT04067830Phase 2Recruiting

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

NCT04430725Active Not Recruiting

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

NCT03634241Phase 2Completed

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

NCT03110978Phase 2Active Not Recruiting

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

NCT03731585Not ApplicableActive Not Recruiting

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

NCT03948100Not ApplicableRecruiting

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

NCT04298606Early Phase 1Completed

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

NCT04505267Phase 1Active Not Recruiting

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

NCT03819296Phase 1Recruiting

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT04013542Phase 1Active Not Recruiting

Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

NCT04428905Phase 3Active Not Recruiting

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

NCT05340309Phase 2Active Not Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

NCT05292521Not ApplicableRecruiting

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

NCT05136846Phase 1Recruiting

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

NCT04348292Phase 1Terminated

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Scroll to load more

Research Network

Activity Timeline